Mihiar Wannousse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mihiar Wannousse has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- He N. Xu
Britton Chance Laboratory of Redox Imaging, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
2 shared publications - Jack Kollmar
Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
2 shared publications - Julia Tchou
Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
2 shared publications - Lin Zhijie Li
Britton Chance Laboratory of Redox Imaging, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
2 shared publications - Alexander A. Shestov
Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
1 shared publication - Allison Podsednik
Britton Chance Laboratory of Redox Imaging, Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
1 shared publication
Latest Publications
- Open Access
Distinct Mitochondrial Recovery Dynamics Following Taxol Removal in Triple-Negative Breast Cancer Cells
Drug resistance in TNBC is associated with metabolic plasticity, yet little is known about how mitochondrial and cellular states evolve after chemotherapeutic withdrawal. We used optical redox imaging (ORI) microscopy and complementary functional measurements to characterize post-Taxol recovery in two TNBC cell lines with different Taxol sensitivities. Whole-dish nuclear counting following 48 h Taxol treatment confirmed that HCC1806 cells responded at lower Taxol concentrations than MDA-MB-436 cells. Recovery was subsequently monitored following extracellular Taxol withdrawal using mitochondrial redox indices, mitochondrial reactive oxygen species (mito-ROS), mitochondrial membrane potential (MMP), multinucleation, and live- and dead-cell counts. HCC1806 cells showed substantial recovery of several mitochondrial parameters and resolution of multinucleation by 96 h; however, a late reductive shift in the optical redox ratio (ORR), reduced MMP, and attenuated live-cell population expansion indicated incomplete redox and functional recovery. In contrast, MDA-MB-436 cells exhibited persistent elevations in Fp and ORR through 144 h, residual multinucleation, and little sustained live-cell population expansion. These findings demonstrate that mitochondrial, multinucleation, and population-level recovery can proceed on different timescales and that post-treatment recovery differs markedly between TNBC models with different Taxol sensitivities. Longitudinal ORI provides a non-destructive approach for characterizing persistent post-treatment metabolic states and, together with functional measurements, may facilitate investigation of recovery-associated phenotypes relevant to therapeutic response.
Open AccessDistinct Mitochondrial Recovery Dynamics Following Taxol Removal in Triple-Negative Breast Cancer Cells
Drug resistance in TNBC is associated with metabolic plasticity, yet little is known about how mitochondrial and cellular states evolve after chemotherapeutic withdrawal. We used optical redox imaging (ORI) microscopy and complementary functional measurements to characterize post-Taxol recovery in two TNBC cell lines with different Taxol sensitivities. Whole-dish nuclear counting following 48 h Taxol treatment confirmed that HCC1806 cells responded at lower Taxol concentrations than MDA-MB-436 cells. Recovery was subsequently monitored following extracellular Taxol withdrawal using mitochondrial redox indices, mitochondrial reactive oxygen species (mito-ROS), mitochondrial membrane potential (MMP), multinucleation, and live- and dead-cell counts. HCC1806 cells showed substantial recovery of several mitochondrial parameters and resolution of multinucleation by 96 h; however, a late reductive shift in the optical redox ratio (ORR), reduced MMP, and attenuated live-cell population expansion indicated incomplete redox and functional recovery. In contrast, MDA-MB-436 cells exhibited persistent elevations in Fp and ORR through 144 h, residual multinucleation, and little sustained live-cell population expansion. These findings demonstrate that mitochondrial, multinucleation, and population-level recovery can proceed on different timescales and that post-treatment recovery differs markedly between TNBC models with different Taxol sensitivities. Longitudinal ORI provides a non-destructive approach for characterizing persistent post-treatment metabolic states and, together with functional measurements, may facilitate investigation of recovery-associated phenotypes relevant to therapeutic response.
- Open Access
- 27 August 2026
- Published by MDPI AG in Metabolites
- Vol. 16 (9) , 613
Live-Cell Optical Redox Imaging Reveals Metabolic Heterogeneity and Context-Dependent Responses to Metabolic Perturbation in TNBC Cells
Background/Objectives: Triple-negative breast cancer (TNBC) exhibits substantial metabolic heterogeneity and plasticity, contributing to variable therapeutic responses. We investigated whether optical redox imaging (ORI) could characterize metabolic phenotypes, monitor responses to metabolic perturbation, and relate these responses to functional outcomes in TNBC cells. Methods: Four TNBC cell lines were treated with the lactate dehydrogenase A inhibitor FX11 or the glutaminase inhibitor CB-839, alone or in combination with paclitaxel. Intensity-based label-free ORI was performed and followed by imaging of fluorescent probes to assess mitochondrial membrane potential (MMP), re-active oxygen species (ROS), and cell number in the same dishes. Seahorse assays were used to evaluate mitochondrial respiration and glycolytic flux. Results: TNBC cell lines exhibited distinct basal redox phenotypes and differential responses to acute glycolytic and glutaminolytic perturbation. HCC1806 cells showed the strongest acute ORI responses to both FX11 and CB-839. Acute FX11 treatment induced a rapid reductive shift accompanied by ROS accumulation and loss of MMP, whereas CB-839 produced a more modest early reductive response without detectable ROS accumulation or MMP loss. Prolonged treatment revealed distinct temporal redox trajectories in HCC1806 cells: FX11-treated cells evolved from an acute reductive response toward a more oxidized state, while CB-839-treated cells transitioned from an early reductive shift to a sustained oxidized redox state accompanied by marked reductions in OCR and ECAR. Functionally, in two representative models (HCC1806 and MDA-MB-231), CB-839 reduced cell numbers and enhanced the anti-proliferative effect of paclitaxel, whereas FX11 had no significant effect on cell number despite inducing pronounced acute redox perturbations. Conclusions: Integrating ORI with metabolic flux assays and imaging-based functional measurements enables characterization of multiple dimensions of metabolic behavior, including basal phenotype, pathway-specific responsiveness, temporal redox responses, and treatment-associated outcomes. These findings support intensity-based wide-field ORI as a practical and accessible tool for probing metabolic heterogeneity and characterizing context-dependent metabolic responses in TNBC cells.
- 27 August 2026
- Published by MDPI AG in Metabolites
- Vol. 16 (9) , 613
Open AccessLive-Cell Optical Redox Imaging Reveals Metabolic Heterogeneity and Context-Dependent Responses to Metabolic Perturbation in TNBC Cells
Background/Objectives: Triple-negative breast cancer (TNBC) exhibits substantial metabolic heterogeneity and plasticity, contributing to variable therapeutic responses. We investigated whether optical redox imaging (ORI) could characterize metabolic phenotypes, monitor responses to metabolic perturbation, and relate these responses to functional outcomes in TNBC cells. Methods: Four TNBC cell lines were treated with the lactate dehydrogenase A inhibitor FX11 or the glutaminase inhibitor CB-839, alone or in combination with paclitaxel. Intensity-based label-free ORI was performed and followed by imaging of fluorescent probes to assess mitochondrial membrane potential (MMP), re-active oxygen species (ROS), and cell number in the same dishes. Seahorse assays were used to evaluate mitochondrial respiration and glycolytic flux. Results: TNBC cell lines exhibited distinct basal redox phenotypes and differential responses to acute glycolytic and glutaminolytic perturbation. HCC1806 cells showed the strongest acute ORI responses to both FX11 and CB-839. Acute FX11 treatment induced a rapid reductive shift accompanied by ROS accumulation and loss of MMP, whereas CB-839 produced a more modest early reductive response without detectable ROS accumulation or MMP loss. Prolonged treatment revealed distinct temporal redox trajectories in HCC1806 cells: FX11-treated cells evolved from an acute reductive response toward a more oxidized state, while CB-839-treated cells transitioned from an early reductive shift to a sustained oxidized redox state accompanied by marked reductions in OCR and ECAR. Functionally, in two representative models (HCC1806 and MDA-MB-231), CB-839 reduced cell numbers and enhanced the anti-proliferative effect of paclitaxel, whereas FX11 had no significant effect on cell number despite inducing pronounced acute redox perturbations. Conclusions: Integrating ORI with metabolic flux assays and imaging-based functional measurements enables characterization of multiple dimensions of metabolic behavior, including basal phenotype, pathway-specific responsiveness, temporal redox responses, and treatment-associated outcomes. These findings support intensity-based wide-field ORI as a practical and accessible tool for probing metabolic heterogeneity and characterizing context-dependent metabolic responses in TNBC cells.